Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have been one of the most in-demand pharmaceutical products in Belarus.
Customer preferences: Belarus has a high demand for antiviral drugs due to the high prevalence of viral infections in the country. The customers in the country have shown a preference for locally manufactured antiviral drugs.
Trends in the market: The market for antiviral drugs in Belarus has been growing steadily over the years. The trend is expected to continue in the coming years due to the increasing prevalence of viral infections in the country. The demand for antiviral drugs has also been driven by the COVID-19 pandemic. The pandemic has led to an increased awareness of the need to protect oneself from viral infections, leading to an increase in demand for antiviral drugs.
Local special circumstances: Belarus has a well-developed pharmaceutical industry, which has been a significant factor in the growth of the antiviral drugs market. The country has been able to produce high-quality antiviral drugs that meet the local demand. Additionally, the government has been supportive of the pharmaceutical industry, providing incentives for local manufacturers to produce antiviral drugs. This has led to an increase in the availability of antiviral drugs in the country.
Underlying macroeconomic factors: The Belarusian economy has been growing steadily over the years, which has led to an increase in the disposable income of the population. This has led to an increase in the demand for antiviral drugs, as people are now able to afford them. The government has also been investing heavily in the healthcare sector, which has led to an increase in the availability of healthcare services, including antiviral drugs. In conclusion, the antiviral drugs market in Belarus has been growing steadily, driven by the high prevalence of viral infections, increasing awareness of the need to protect oneself from viral infections, a well-developed pharmaceutical industry, and a supportive government. The trend is expected to continue in the coming years, driven by the underlying macroeconomic factors in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
